NCDR report finds hospitals are seeing improvements but are still struggling to reach pre-COVID treatment thresholds years after pandemic precautions upended longstanding processes.

This encouraged the study’s authors, who had feared any history of smoking on a regular basis would do permanent, irreversible damage to a patient's cardiovascular health. 

Researchers examined data from nearly 60,000 adults, focusing on individuals who have been diagnosed with Cannabis Use Disorder. 

How common is it for patients to present with overlapping cardiac, renal and metabolic issues? A new analysis in JAMA Cardiology explored that very question.

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

That same team that transplanted a pig heart into a human patient for the very first time in 2022 has now done it again. The patient is currently recovering from the procedure, which occurred on Sept. 20. 

Access to cannabis is skyrocketing across the United States, but much more research is still needed on its long-term side effects. 

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved.